Ergun Hakan, Gulmez Sinem Ezgi, Tulunay F Cankat
Department of Pharmacology and Clinical Pharmacology, Ankara University Faculty of Medicine, Ankara, Turkey.
Eur Neurol. 2007;58(4):215-7. doi: 10.1159/000107942. Epub 2007 Sep 7.
Migraine is a common disorder with a relatively high burden of disease from the perspective of both society and the individual patient. Optimizing the use of prophylactic treatment may decrease the frequency and severity of attacks thus reducing the burden of disease. In this regard, topiramate has been found to be as effective as propranolol in the prevention of migraine attacks. In the present study, a cost-minimization analysis was performed. Monthly preventive medication cost and price per migraine attack reduced were used as measures. In comparison with propranolol and flunarizine, topiramate was identified as being the most costly option for migraine prophylaxis with a monthly drug cost of USD 24.97-45.04 as compared with propranolol (USD 1.72-6.87) and flunarizine (USD 6.09-12.18). Current treatment options would appear to offer better value for money in achieving effective migraine prophylaxis unless additional benefits can be identified for topiramate in this patient group.
偏头痛是一种常见疾病，从社会和个体患者的角度来看，其疾病负担相对较高。优化预防性治疗的使用可能会降低发作的频率和严重程度，从而减轻疾病负担。在这方面，已发现托吡酯在预防偏头痛发作方面与普萘洛尔一样有效。在本研究中，进行了成本最小化分析。采用每月预防性药物成本和每次偏头痛发作减少的费用作为衡量指标。与普萘洛尔和氟桂利嗪相比，托吡酯被确定为预防偏头痛最昂贵的选择，每月药物成本为24.97 - 45.04美元，而普萘洛尔为1.72 - 6.87美元，氟桂利嗪为6.09 - 12.18美元。除非能确定托吡酯对该患者群体有额外益处，否则目前的治疗选择在实现有效的偏头痛预防方面似乎性价比更高。
